

# Virbac

Go back to [homepage](#)

Virbac	
Financial Details	
<b>Total Company Revenue in 2010</b>	\$ 0.781 Bn
<b>Revenue from Animal Health Market in 2010</b>	\$ 0.781 Bn
<b>% of revenue from Animal Health in 2010</b>	100% (The company is only into Animal Health)
Segmentwise Revenue Breakup (\$ Bn)	
<b>Livestock Vaccines</b>	0.294
<b>Companion Vaccines</b>	0.469
Number of Major Vaccines (Animal-wise)	
<b>Poultry</b>	0
<b>Swine</b>	0
<b>Fish</b>	0
<b>Sheep</b>	0
<b>Cattle</b>	0
<b>Canine</b>	6
<b>Feline</b>	2
<b>Equine</b>	0
Mergers and Acquisitions (2009 - 2011)	
Consideration	
<b>Santa Elena laboratory</b>	\$ 3.7 Mn
<b>Veterinary Assets from Pfizer Inc.</b>	undisclosed
Future Focus Areas	
<b>Veterinary Vaccines under trial</b>	0
<b>Future Focus Areas of the company in the Veterinary Vaccines Market</b>	Bacterian and virus vaccines Parasiticides and vaccines for cattle and sheep

Go back to [homepage](#)